JP2015509947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509947A5 JP2015509947A5 JP2014558882A JP2014558882A JP2015509947A5 JP 2015509947 A5 JP2015509947 A5 JP 2015509947A5 JP 2014558882 A JP2014558882 A JP 2014558882A JP 2014558882 A JP2014558882 A JP 2014558882A JP 2015509947 A5 JP2015509947 A5 JP 2015509947A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- isolated monoclonal
- seq
- antibody
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603173P | 2012-02-24 | 2012-02-24 | |
| US61/603,173 | 2012-02-24 | ||
| US201261719803P | 2012-10-29 | 2012-10-29 | |
| US61/719,803 | 2012-10-29 | ||
| PCT/US2013/027391 WO2013126746A2 (en) | 2012-02-24 | 2013-02-22 | Novel modulators and methods of use |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016030269A Division JP6010241B2 (ja) | 2012-02-24 | 2016-02-19 | Ｄｌｌ３モジュレーター及び使用方法 |
| JP2016030270A Division JP2016098233A (ja) | 2012-02-24 | 2016-02-19 | Ｄｌｌ３モジュレーター及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509947A JP2015509947A (ja) | 2015-04-02 |
| JP2015509947A5 true JP2015509947A5 (enExample) | 2016-04-07 |
| JP6089047B2 JP6089047B2 (ja) | 2017-03-01 |
Family
ID=47790544
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558882A Expired - Fee Related JP6089047B2 (ja) | 2012-02-24 | 2013-02-22 | Ｄｌｌ３モジュレーター及び使用方法 |
| JP2016030269A Expired - Fee Related JP6010241B2 (ja) | 2012-02-24 | 2016-02-19 | Ｄｌｌ３モジュレーター及び使用方法 |
| JP2016030270A Pending JP2016098233A (ja) | 2012-02-24 | 2016-02-19 | Ｄｌｌ３モジュレーター及び使用方法 |
| JP2018102094A Pending JP2018162257A (ja) | 2012-02-24 | 2018-05-29 | Ｄｌｌ３モジュレーター及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016030269A Expired - Fee Related JP6010241B2 (ja) | 2012-02-24 | 2016-02-19 | Ｄｌｌ３モジュレーター及び使用方法 |
| JP2016030270A Pending JP2016098233A (ja) | 2012-02-24 | 2016-02-19 | Ｄｌｌ３モジュレーター及び使用方法 |
| JP2018102094A Pending JP2018162257A (ja) | 2012-02-24 | 2018-05-29 | Ｄｌｌ３モジュレーター及び使用方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (31) | US9090683B2 (enExample) |
| EP (4) | EP3093294A1 (enExample) |
| JP (4) | JP6089047B2 (enExample) |
| KR (1) | KR20150003169A (enExample) |
| CN (1) | CN104520324A (enExample) |
| AU (3) | AU2013203459B2 (enExample) |
| BR (1) | BR112014020826A8 (enExample) |
| CA (2) | CA2865404C (enExample) |
| CL (2) | CL2014002240A1 (enExample) |
| CO (1) | CO7111274A2 (enExample) |
| CY (1) | CY1119590T1 (enExample) |
| DK (1) | DK2817338T3 (enExample) |
| ES (2) | ES2812849T3 (enExample) |
| HK (3) | HK1231485A1 (enExample) |
| HR (1) | HRP20171549T1 (enExample) |
| HU (1) | HUE037021T2 (enExample) |
| IL (2) | IL234155B (enExample) |
| LT (1) | LT2817338T (enExample) |
| ME (1) | ME02928B (enExample) |
| MX (2) | MX2014010074A (enExample) |
| NZ (1) | NZ628804A (enExample) |
| PE (2) | PE20190658A1 (enExample) |
| PH (1) | PH12014501876A1 (enExample) |
| PL (1) | PL2817338T3 (enExample) |
| PT (1) | PT2817338T (enExample) |
| RS (1) | RS56443B1 (enExample) |
| RU (1) | RU2014138474A (enExample) |
| SG (2) | SG11201405131XA (enExample) |
| SI (1) | SI2817338T1 (enExample) |
| SM (1) | SMT201700467T1 (enExample) |
| WO (1) | WO2013126746A2 (enExample) |
Families Citing this family (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2530091T (lt) | 2010-01-29 | 2018-06-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antikūnas |
| EP3093294A1 (en) | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Dll3 modulators and methods of use |
| US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| RU2019109456A (ru) | 2013-02-22 | 2019-04-10 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Новые конъюгаты антител и их применения |
| KR20160047567A (ko) * | 2013-08-28 | 2016-05-02 | 스템센트알엑스 인코포레이티드 | 조작된 항-dll3 접합체 및 사용 방법 |
| WO2015031698A1 (en) | 2013-08-28 | 2015-03-05 | Stem Centrx, Inc. | Site-specific antibody conjugation methods and compositions |
| SG11201510740YA (en) | 2013-09-17 | 2016-01-28 | Obi Pharma Inc | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
| CN105940107B (zh) | 2013-11-11 | 2021-06-15 | 中外制药株式会社 | 含有改变了抗体可变区的抗原结合分子 |
| TWI700295B (zh) | 2013-12-16 | 2020-08-01 | 馬來西亞商Ｍａｂ探索私人有限公司 | 對會感染人類之腸病毒具有專一性之抗體 |
| KR20170008202A (ko) | 2014-02-21 | 2017-01-23 | 애브비 스템센트알엑스 엘엘씨 | 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체 |
| EP3662928A1 (en) | 2014-04-10 | 2020-06-10 | OBI Pharma Inc. | Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof |
| US9732145B2 (en) * | 2014-07-31 | 2017-08-15 | The Israel Institute of Biological Research (IIBR) | Antibodies directed to Bacillus anthracis protective antigen |
| ES2743809T3 (es) | 2014-07-31 | 2020-02-20 | Amgen Res Munich Gmbh | Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados |
| TWI740809B (zh) | 2014-11-11 | 2021-10-01 | 日商中外製藥股份有限公司 | 包含經改變之抗體可變區之抗原結合分子的資料庫 |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| SG10202110908WA (en) * | 2015-05-04 | 2021-11-29 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
| ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
| JP2018524313A (ja) * | 2015-06-23 | 2018-08-30 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｂ７ｈ３抗体との抗体薬物複合体 |
| US11319528B2 (en) | 2015-07-13 | 2022-05-03 | University Of Utah Research Foundation | Methods of making red blood cells and platelets in vitro and uses thereof |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究（慕尼黑）公司 | Dll3及cd3抗體構築體 |
| JP2018529656A (ja) * | 2015-08-20 | 2018-10-11 | アッヴィ・ステムセントルクス・エル・エル・シー | 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法 |
| JP2018532990A (ja) | 2015-09-04 | 2018-11-08 | オービーアイ ファーマ，インコーポレイテッド | グリカンアレイおよび使用の方法 |
| WO2017095808A1 (en) | 2015-11-30 | 2017-06-08 | Abbvie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
| US10188660B2 (en) | 2015-11-30 | 2019-01-29 | Abbvie Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| EA039325B1 (ru) * | 2016-02-03 | 2022-01-13 | Эмджен Рисерч (Мюник) Гмбх | Конструкции биспецифических антител, связывающиеся с дпб3 (dll3) и кд3 (cd3) |
| TN2018000266A1 (en) | 2016-02-03 | 2020-01-16 | Amgen Res Munich Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs. |
| WO2017157505A1 (en) | 2016-03-17 | 2017-09-21 | Merck Patent Gmbh | Method for purifying poloxamers |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| TWI780045B (zh) * | 2016-03-29 | 2022-10-11 | 台灣浩鼎生技股份有限公司 | 抗體、醫藥組合物及方法 |
| US10934347B2 (en) * | 2016-04-04 | 2021-03-02 | Genzyme Corporation | Anti-complement factor BB antibodies and uses thereof |
| AU2017252128B2 (en) | 2016-04-22 | 2024-06-06 | Obi Pharma, Inc. | Cancer immunotherapy by immune activation or immune modulation via Globo series antigens |
| CA3024723A1 (en) | 2016-05-20 | 2017-11-23 | Robert B. Dubridge | Single domain serum albumin binding protein |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| MX2018016330A (es) | 2016-06-27 | 2020-02-17 | Univ California | Combinaciones para tratamiento del cáncer. |
| KR20230117482A (ko) | 2016-07-27 | 2023-08-08 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| JP7121724B2 (ja) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ，インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
| KR20190035863A (ko) | 2016-08-05 | 2019-04-03 | 알라코스 인크. | 암 치료를 위한 항Siglec-7 항체 |
| US10042362B2 (en) | 2016-11-18 | 2018-08-07 | Waymo Llc | Dynamic routing for autonomous vehicles |
| WO2018094414A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| US11987625B2 (en) | 2016-11-22 | 2024-05-21 | Dendrocyte Biotech Pty Ltd | Anti-CD300F antibody and uses thereof |
| KR20190087539A (ko) | 2016-11-23 | 2019-07-24 | 하푼 테라퓨틱스, 인크. | Psma 표적화 삼중특이성 단백질 및 사용 방법 |
| EP3544997A4 (en) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN |
| WO2018102795A2 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| GB201700553D0 (en) * | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| CN115028727A (zh) | 2017-05-12 | 2022-09-09 | 哈普恩治疗公司 | 靶向msln的三特异性蛋白质及使用方法 |
| BR112019023855B1 (pt) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | Proteínas de ligação à mesotelina |
| EP3661555B1 (en) | 2017-08-01 | 2025-04-16 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| US11192944B2 (en) | 2017-10-11 | 2021-12-07 | Bioverativ Usa Inc. | Methods of inducing complement activity |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| JP7084990B2 (ja) | 2017-10-13 | 2022-06-15 | ハープーン セラピューティクス，インク． | 三重特異性タンパク質と使用方法 |
| EP3720963A4 (en) | 2017-12-05 | 2021-12-08 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137 |
| WO2019131988A1 (en) | 2017-12-28 | 2019-07-04 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| WO2019140273A1 (en) * | 2018-01-11 | 2019-07-18 | Allakos, Inc. | Anti-siglec-7 antibodies having reduced effector function |
| WO2019195408A1 (en) * | 2018-04-03 | 2019-10-10 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting dll3, and use thereof |
| EP3773630A1 (en) | 2018-04-03 | 2021-02-17 | Promab Biotechnologies, Inc. | Bcma-car-t cells |
| UA129466C2 (uk) * | 2018-04-10 | 2025-05-07 | Емджен Інк. | Химерні рецептори до dll3 та способи їх застосування |
| BR112020021280A2 (pt) * | 2018-05-08 | 2021-01-26 | Phanes Therapeutics, Inc. | anticorpos anti-dll3 e usos dos mesmos |
| WO2019222283A1 (en) | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| TWI853822B (zh) | 2018-06-27 | 2024-09-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2019316103B2 (en) | 2018-08-02 | 2026-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12497464B1 (en) | 2018-08-03 | 2025-12-16 | Berkeley Therapeutics, Inc. | Antibody, antibody fragments or peptide for treating cancer and methods of formation and administration |
| CN113286824A (zh) | 2018-08-03 | 2021-08-20 | 中外制药株式会社 | 包含两个彼此连接的抗原结合结构域的抗原结合分子 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113286817B (zh) | 2018-09-25 | 2025-01-28 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| WO2020069349A1 (en) * | 2018-09-27 | 2020-04-02 | Colorado State University Research Foundation | Scfv's for live cell imaging and other uses |
| EP3856789A4 (en) | 2018-09-28 | 2022-08-17 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE WITH VARIABLE REGION OF AN ALTERED ANTIBODY |
| KR20210125978A (ko) | 2018-11-01 | 2021-10-19 | 그라셀 바이오테크놀로지스 (상하이) 컴퍼니, 리미티드 | T 세포 조작을 위한 조성물 및 방법 |
| CN111647082B (zh) * | 2018-12-27 | 2023-02-17 | 中山康方生物医药有限公司 | 抗人il-4ra的抗体及其用途 |
| US12463463B2 (en) | 2019-01-28 | 2025-11-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| EP3927744A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| MX2021010441A (es) | 2019-03-01 | 2021-09-21 | Allogene Therapeutics Inc | Receptores antigenicos quimericos y agentes de union dirigidos a dll3. |
| CN113874526A (zh) * | 2019-03-08 | 2021-12-31 | 肿瘤实验室诊断有限公司 | 癌症的诊断和预后 |
| BR112021016272A2 (pt) * | 2019-04-08 | 2021-11-09 | Phanes Therapeutics Inc | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos |
| WO2020219959A1 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anti-cd45 antibody drug conjugates and uses thereof |
| US12516128B2 (en) | 2019-05-14 | 2026-01-06 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| US20220313845A1 (en) * | 2019-06-07 | 2022-10-06 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| BR112022000216A2 (pt) | 2019-07-11 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Anticorpos direcionados a dll3 e usos dos mesmos |
| WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| CN112442126B (zh) | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| EP4084823A4 (en) | 2020-01-03 | 2024-05-15 | Marengo Therapeutics, Inc. | ANTI-TCR ANTIBODY MOLECULES AND THEIR USES |
| EP4087653A4 (en) * | 2020-01-10 | 2024-06-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| BR112022013577A2 (pt) | 2020-01-10 | 2022-09-13 | Rhode Island Hospital | Anticorpos pfgarp para matar parasitas da malária plasmodium falciparum e proteger contra infecções e doenças severas |
| CA3163608A1 (en) * | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
| AU2021205346A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| KR20220125801A (ko) * | 2020-01-10 | 2022-09-14 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| US20230117883A1 (en) * | 2020-01-24 | 2023-04-20 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| US20230075244A1 (en) * | 2020-02-20 | 2023-03-09 | The Feinstein Institutes For Medical Research | Agonist antibodies against endoglin and uses thereof |
| IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
| EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| WO2021173307A1 (en) * | 2020-02-25 | 2021-09-02 | Gensun Biopharma Inc. | Trispecific t cell engagers |
| TWI799824B (zh) | 2020-03-31 | 2023-04-21 | 日商中外製藥股份有限公司 | Ｄｌｌ３靶向之多特異性抗原結合分子及其用途 |
| CN115335410A (zh) | 2020-03-31 | 2022-11-11 | 中外制药株式会社 | 生产多特异性抗原结合分子的方法 |
| WO2021216458A1 (en) | 2020-04-20 | 2021-10-28 | Genzyme Corporation | Humanized anti-complement factor bb antibodies and uses thereof |
| WO2021216832A1 (en) * | 2020-04-23 | 2021-10-28 | Remd Biotherapeutics, Inc. | Chemokine receptor 4 (cxcr4) antagonist antibodies |
| CR20220611A (es) * | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Anti-asgr1 antibody conjugates and uses thereof |
| EP4214233A1 (en) | 2020-09-16 | 2023-07-26 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| US20230391855A1 (en) * | 2020-10-21 | 2023-12-07 | La Jolla Institute For Immunology | Chimeric anti-sars-cov2 nucleoprotein antibodies |
| AU2021372988A1 (en) * | 2020-11-06 | 2023-06-22 | Board Of Regents, The University Of Texas System | Methods and systems for classification and treatment of small cell lung cancer |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| CA3204731A1 (en) | 2021-01-13 | 2022-07-21 | John T. POIRIER | Anti-dll3 antibody-drug conjugate |
| TW202237135A (zh) | 2021-01-13 | 2022-10-01 | 紀念斯隆凱特琳癌症中心 | 抗體-吡咯并苯并二氮呯衍生物結合物 |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN113528583A (zh) * | 2021-07-15 | 2021-10-22 | 澳门大学 | 自动化显微注射方法、装置、系统、设备及存储介质 |
| CA3226938A1 (en) | 2021-07-30 | 2023-02-02 | Qingsong GUO | Anti-dll3 antibody and preparation method therefor, drug conjugate and application thereof |
| MX2024002121A (es) * | 2021-08-19 | 2024-07-10 | Adicet Therapeutics Inc | Métodos para la detección del glipicano-3 unido a la membrana. |
| WO2023053272A1 (en) | 2021-09-29 | 2023-04-06 | Chugai Seiyaku Kabushiki Kaisha | Uses of dll3-targeting multispecific antigen-binding molecules |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| US20250270328A1 (en) * | 2022-05-18 | 2025-08-28 | The Brigham And Women's Hospital, Inc. | Klrb1 binding agents and methods of use thereof |
| CN119019548B (zh) * | 2022-07-05 | 2025-06-24 | 东莞市朋志生物科技有限公司 | 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒 |
| CN116355079B (zh) * | 2022-08-19 | 2023-12-26 | 上海迈科康生物科技有限公司 | 检测重组人轮状病毒vp8抗原（vp8 p[8]）的单克隆抗体及其应用 |
| IL319125A (en) | 2022-08-22 | 2025-04-01 | Abdera Therapeutics Inc | DLL3 binding molecules and their uses |
| CN116731184B (zh) * | 2022-11-25 | 2024-06-14 | 厦门康基生物科技有限公司 | 一种特异性结合Taq酶的单克隆抗体F6H12及其应用 |
| CN120265651A (zh) | 2022-11-25 | 2025-07-04 | 中外制药株式会社 | 用于生产蛋白质的方法 |
| IL320471A (en) * | 2022-12-08 | 2025-06-01 | Amgen Inc | Methods for treating DLL3-expressing cancers |
| CN116173202A (zh) * | 2022-12-28 | 2023-05-30 | 北京东方百泰生物科技股份有限公司 | 一种抗lilrb4单克隆抗体注射制剂 |
| US20250011368A1 (en) * | 2023-06-14 | 2025-01-09 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| CN121712787A (zh) * | 2023-06-14 | 2026-03-20 | 马里亚纳肿瘤学公司 | 靶向dll3的肽及其构建体 |
| WO2024259147A1 (en) * | 2023-06-14 | 2024-12-19 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| CN119490592B (zh) * | 2023-08-14 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 一种抗κ型轻链抗体及其应用 |
| CN116966202B (zh) * | 2023-09-22 | 2023-12-01 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成的神经干细胞联合药物用于治疗阿尔茨海默症的用途 |
| WO2025085796A1 (en) * | 2023-10-18 | 2025-04-24 | Memorial Sloan-Kettering Cancer Center | Armored immunoresponsive cells targeting dll3 and uses thereof |
| WO2025179168A1 (en) * | 2024-02-22 | 2025-08-28 | Mariana Oncology Inc. | Synthesis of dll3-binding peptides |
| WO2025250696A1 (en) * | 2024-05-28 | 2025-12-04 | New York University | Anti-ttyh2 antibodies and methods of use thereof |
| CN120137041B (zh) * | 2025-03-14 | 2025-11-28 | 深圳市欧安蒂生物科技有限公司 | 一种抗gprc5d抗体及其在car-t中的应用 |
| CN120350014B (zh) * | 2025-06-26 | 2025-08-22 | 上海交通大学医学院附属仁济医院 | 核酸适体、核酸适体衍生物及其应用 |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69123241T2 (de) | 1990-12-14 | 1997-04-17 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| WO1994004670A1 (en) | 1992-08-26 | 1994-03-03 | President And Fellows Of Harvard College | Use of the cytokine ip-10 as an anti-tumor agent |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DK0804070T3 (da) | 1993-03-09 | 2000-08-07 | Genzyme Corp | Fremgangsmåde til isolering af proteiner fra mælk |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| PL178381B1 (pl) | 1994-07-13 | 2000-04-28 | Sca Hygiene Paper Ab | Sposób wytwarzania włókniny |
| CA2196200A1 (en) | 1994-07-29 | 1996-02-15 | Michael Joseph Browne | Novel compounds |
| US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
| US20030180784A1 (en) * | 1997-04-04 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | Novel human Delta3 compositions and therapeutic and diagnostic uses therefor |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| DE69839060T2 (de) | 1997-11-03 | 2009-01-15 | Human Genome Sciences, Inc. | Vegi, ein inhibitor der angiogenese und des tumorwachstums |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| CA2341471C (en) | 1998-08-27 | 2009-04-07 | Spirogen Limited | Pyrrolbenzodiazepines |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6908748B2 (en) | 1999-07-29 | 2005-06-21 | Kenji Sobue | Genes associated with the maintenance of differentiation of smooth muscle cells |
| US6703221B1 (en) | 1999-08-19 | 2004-03-09 | Chiron Corporation | Notch receptor ligands and uses thereof |
| WO2001012664A2 (en) | 1999-08-19 | 2001-02-22 | Chiron Corporation | Notch receptor ligands and uses thereof |
| JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| AU2001280471A1 (en) | 2000-08-11 | 2002-02-25 | Eli Lilly And Company | Novel secreted proteins and their uses |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| DE10131904A1 (de) | 2001-07-04 | 2003-01-16 | Putzmeister Ag | Vorrichtung zum Fördern von fließ- oder schüttfähigem Fördergut |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| JP2005533001A (ja) | 2002-03-04 | 2005-11-04 | メディミューン，インコーポレーテッド | インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法 |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| EP1633784B1 (en) | 2003-05-09 | 2011-07-13 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| EP1654383A1 (en) | 2003-08-08 | 2006-05-10 | Licentia, Ltd. | Materials and methods for colorectal cancer screening, diagnosis, and therapy |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CA2558195C (en) | 2004-03-01 | 2012-11-06 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| BRPI0620695A2 (pt) | 2005-12-16 | 2011-11-22 | Genentech, Inc | método para tratar um tumor do tipo glioma, métodos de prognóstico e/ou diagnóstico de glioma, método de monitoramento ou diagnóstico, método para inibir o tamanho ou crescimento de um tumor do tipo glioma, métodos para tratar terapeuticamente, método para determinar o nìvel de expressão de marcadores determinantes de glioma ("gdm") de pn, prolif ou mes, método para prognosticar o tempo de sobrevida, método para diagnosticar a severidade de um tumor do tipo glioma e uso |
| WO2007080597A2 (en) | 2006-01-16 | 2007-07-19 | Compugen Ltd. | Polynucleotide and polypeptide sequences and methods for diagnosis |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| US8133857B2 (en) | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
| CA2658003A1 (en) | 2006-06-06 | 2007-12-21 | University Of Tennessee Research Foundation | Compositions enriched in neoplastic stem cells and methods comprising same |
| PL3207941T6 (pl) | 2006-09-07 | 2020-11-16 | Scott & White Memorial Hospital | Sposoby i kompozycje oparte na koniugacie ludzkiej interleukiny (IL)-3 z toksyną błoniczą |
| US7825267B2 (en) | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| US20100061933A1 (en) | 2006-10-20 | 2010-03-11 | Naoki Kimura | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| US8309354B2 (en) | 2007-01-22 | 2012-11-13 | Macrogenics West, Inc. | Human cancer stem cells |
| WO2009012357A2 (en) | 2007-07-17 | 2009-01-22 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| US20090130105A1 (en) | 2007-08-28 | 2009-05-21 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| US20090155255A1 (en) | 2007-09-27 | 2009-06-18 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| WO2009124931A2 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
| US8384551B2 (en) | 2008-05-28 | 2013-02-26 | MedHab, LLC | Sensor device and method for monitoring physical stresses placed on a user |
| WO2010037134A2 (en) | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| US8788213B2 (en) | 2009-01-12 | 2014-07-22 | Intrexon Corporation | Laser mediated sectioning and transfer of cell colonies |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| LT2530091T (lt) * | 2010-01-29 | 2018-06-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antikūnas |
| WO2011130598A1 (en) * | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| KR101772354B1 (ko) | 2010-04-15 | 2017-08-28 | 시애틀 지네틱스, 인크. | 표적화된 피롤로벤조디아제핀 접합체 |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| CN106434561A (zh) | 2010-09-03 | 2017-02-22 | 艾伯维施特姆森特克斯有限责任公司 | 细胞亚群的鉴定和富集 |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| MX347954B (es) | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| BR112013021460B1 (pt) | 2011-03-02 | 2022-12-20 | Roche Glycart Ag | Anticorpos, composição e uso do anticorpo |
| WO2013041606A1 (en) | 2011-09-20 | 2013-03-28 | Spirogen Sàrl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| FI3536710T3 (fi) | 2011-11-16 | 2026-01-14 | Boehringer Ingelheim Int | Anti-il-36r -vasta-aineita |
| EP3093294A1 (en) | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Dll3 modulators and methods of use |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| RU2019109456A (ru) | 2013-02-22 | 2019-04-10 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Новые конъюгаты антител и их применения |
| US9683039B2 (en) | 2013-03-14 | 2017-06-20 | New York University | Notch agonists for the treatment of cancer |
| KR20160047567A (ko) | 2013-08-28 | 2016-05-02 | 스템센트알엑스 인코포레이티드 | 조작된 항-dll3 접합체 및 사용 방법 |
| WO2015031698A1 (en) | 2013-08-28 | 2015-03-05 | Stem Centrx, Inc. | Site-specific antibody conjugation methods and compositions |
| KR20170008202A (ko) | 2014-02-21 | 2017-01-23 | 애브비 스템센트알엑스 엘엘씨 | 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체 |
| EP3209334A2 (en) | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| WO2018026742A1 (en) | 2016-08-01 | 2018-02-08 | Askgene Pharma Inc. | Novel antibody-albumin-drug conjugates (aadc) and methods for using them |
-
2013
- 2013-02-22 EP EP16164551.0A patent/EP3093294A1/en not_active Withdrawn
- 2013-02-22 EP EP13707525.5A patent/EP2817338B1/en active Active
- 2013-02-22 ES ES16164567T patent/ES2812849T3/es active Active
- 2013-02-22 SI SI201330800T patent/SI2817338T1/sl unknown
- 2013-02-22 SM SM20170467T patent/SMT201700467T1/it unknown
- 2013-02-22 CA CA2865404A patent/CA2865404C/en active Active
- 2013-02-22 PE PE2019000670A patent/PE20190658A1/es unknown
- 2013-02-22 NZ NZ628804A patent/NZ628804A/en not_active IP Right Cessation
- 2013-02-22 JP JP2014558882A patent/JP6089047B2/ja not_active Expired - Fee Related
- 2013-02-22 AU AU2013203459A patent/AU2013203459B2/en not_active Ceased
- 2013-02-22 HU HUE13707525A patent/HUE037021T2/hu unknown
- 2013-02-22 SG SG11201405131XA patent/SG11201405131XA/en unknown
- 2013-02-22 WO PCT/US2013/027391 patent/WO2013126746A2/en not_active Ceased
- 2013-02-22 HR HRP20171549TT patent/HRP20171549T1/hr unknown
- 2013-02-22 RS RS20171006A patent/RS56443B1/sr unknown
- 2013-02-22 DK DK13707525.5T patent/DK2817338T3/en active
- 2013-02-22 PE PE2014001295A patent/PE20150090A1/es active IP Right Grant
- 2013-02-22 ME MEP-2017-185A patent/ME02928B/me unknown
- 2013-02-22 EP EP16164549.4A patent/EP3093293A1/en not_active Withdrawn
- 2013-02-22 BR BR112014020826A patent/BR112014020826A8/pt not_active Application Discontinuation
- 2013-02-22 PT PT137075255T patent/PT2817338T/pt unknown
- 2013-02-22 EP EP16164567.6A patent/EP3095797B1/en active Active
- 2013-02-22 KR KR1020147026844A patent/KR20150003169A/ko not_active Ceased
- 2013-02-22 RU RU2014138474A patent/RU2014138474A/ru not_active Application Discontinuation
- 2013-02-22 MX MX2014010074A patent/MX2014010074A/es unknown
- 2013-02-22 ES ES13707525.5T patent/ES2645272T3/es active Active
- 2013-02-22 CN CN201380010475.2A patent/CN104520324A/zh active Pending
- 2013-02-22 LT LTEP13707525.5T patent/LT2817338T/lt unknown
- 2013-02-22 PL PL13707525T patent/PL2817338T3/pl unknown
- 2013-02-22 CA CA3050672A patent/CA3050672A1/en not_active Abandoned
- 2013-02-22 SG SG10201806867VA patent/SG10201806867VA/en unknown
-
2014
- 2014-08-17 IL IL234155A patent/IL234155B/en active IP Right Grant
- 2014-08-20 PH PH12014501876A patent/PH12014501876A1/en unknown
- 2014-08-21 MX MX2018010548A patent/MX2018010548A/es unknown
- 2014-08-22 US US14/466,948 patent/US9090683B2/en not_active Expired - Fee Related
- 2014-08-22 US US14/466,941 patent/US9107961B2/en not_active Expired - Fee Related
- 2014-08-22 US US14/466,951 patent/US9089617B2/en not_active Expired - Fee Related
- 2014-08-22 CO CO14184798A patent/CO7111274A2/es unknown
- 2014-08-22 US US14/466,945 patent/US9089616B2/en not_active Expired - Fee Related
- 2014-08-22 US US14/466,939 patent/US8986972B2/en active Active
- 2014-08-22 CL CL2014002240A patent/CL2014002240A1/es unknown
- 2014-08-22 US US14/466,842 patent/US9089615B2/en not_active Expired - Fee Related
-
2015
- 2015-01-19 HK HK17104908.4A patent/HK1231485A1/en unknown
- 2015-01-19 HK HK17104910.0A patent/HK1231486A1/en unknown
- 2015-01-19 HK HK17104918.2A patent/HK1231488A1/en unknown
- 2015-06-08 US US14/733,874 patent/US9155803B1/en not_active Expired - Fee Related
- 2015-06-17 US US14/742,576 patent/US9133271B1/en not_active Expired - Fee Related
- 2015-07-23 US US14/807,789 patent/US9173959B1/en active Active
- 2015-09-18 US US14/859,242 patent/US9353182B2/en not_active Expired - Fee Related
-
2016
- 2016-01-11 US US14/992,714 patent/US9334318B1/en active Active
- 2016-01-25 US US15/005,993 patent/US9358304B1/en not_active Expired - Fee Related
- 2016-01-25 US US15/005,918 patent/US9345784B1/en not_active Expired - Fee Related
- 2016-01-25 US US15/005,962 patent/US9352051B1/en not_active Expired - Fee Related
- 2016-02-19 JP JP2016030269A patent/JP6010241B2/ja not_active Expired - Fee Related
- 2016-02-19 JP JP2016030270A patent/JP2016098233A/ja active Pending
- 2016-04-21 US US15/135,517 patent/US9486537B2/en not_active Expired - Fee Related
- 2016-04-21 US US15/135,542 patent/US9480757B2/en not_active Expired - Fee Related
- 2016-04-21 US US15/135,546 patent/US9481727B2/en not_active Expired - Fee Related
- 2016-06-22 CL CL2016001616A patent/CL2016001616A1/es unknown
- 2016-09-15 US US15/266,894 patent/US10137204B2/en active Active
- 2016-10-14 AU AU2016244333A patent/AU2016244333B2/en not_active Ceased
-
2017
- 2017-05-30 US US15/608,995 patent/US9764042B1/en not_active Expired - Fee Related
- 2017-05-30 US US15/608,991 patent/US9878053B2/en not_active Expired - Fee Related
- 2017-05-30 US US15/608,996 patent/US9775916B1/en not_active Expired - Fee Related
- 2017-05-30 US US15/608,988 patent/US9770518B1/en not_active Expired - Fee Related
- 2017-06-07 US US15/616,192 patent/US9861708B2/en not_active Expired - Fee Related
- 2017-06-07 US US15/616,800 patent/US9855343B2/en not_active Expired - Fee Related
- 2017-09-01 US US15/694,622 patent/US9867887B1/en not_active Expired - Fee Related
- 2017-09-01 US US15/694,627 patent/US9931421B2/en not_active Expired - Fee Related
- 2017-09-01 US US15/694,629 patent/US9937268B2/en not_active Expired - Fee Related
- 2017-09-01 US US15/694,602 patent/US9931420B2/en not_active Expired - Fee Related
- 2017-10-20 CY CY20171101098T patent/CY1119590T1/el unknown
-
2018
- 2018-05-29 JP JP2018102094A patent/JP2018162257A/ja active Pending
- 2018-10-03 IL IL262110A patent/IL262110A/en unknown
- 2018-10-25 US US16/170,848 patent/US20190046656A1/en not_active Abandoned
- 2018-12-19 AU AU2018282328A patent/AU2018282328A1/en not_active Abandoned
-
2019
- 2019-04-12 US US16/382,868 patent/US20190247510A1/en not_active Abandoned
- 2019-12-06 US US16/706,174 patent/US11033634B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509947A5 (enExample) | ||
| JP2015509948A5 (enExample) | ||
| JP2016510002A5 (enExample) | ||
| JP2016538318A5 (enExample) | ||
| JP2018127469A5 (enExample) | ||
| JP2016098233A5 (enExample) | ||
| HRP20191169T1 (hr) | Konjugati antidll3-protutijelo-pbd i njihove uporabe | |
| JP2016536020A5 (enExample) | ||
| JP2017500028A5 (enExample) | ||
| JP2020520370A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| JP2017510559A5 (enExample) | ||
| JP2015533781A5 (enExample) | ||
| JP2017512765A5 (enExample) | ||
| RU2016145277A (ru) | Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака | |
| JP2017534577A5 (enExample) | ||
| JP2017519759A5 (enExample) | ||
| ME02928B (me) | Dll3 modulatori i metode upotrebe | |
| PE20140848A1 (es) | Anticuerpos monoclonales contra la proteina rgma y sus usos | |
| JP2014522850A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| JP2014509835A5 (enExample) | ||
| JP2016503067A5 (enExample) | ||
| JP2010520290A5 (enExample) |